Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23178981 | 1.00 | PDK1 (0.36) | PDK1GAAMGAMTP53CYP3A4 | |
| SCHEMBL16392595 | 0.80 | GAA (0.31) | GAAMGAMTP53CYP3A4ALOX15 | |
| SCHEMBL25668004 | 0.80 | GAA (0.35) | PDK1GAAMGAMTP53CYP3A4 | |
| SCHEMBL4740611 | 0.80 | GAA (0.35) | PDK1GAAMGAMTP53CYP3A4 | |
| SCHEMBL23206546 | 0.80 | GAA (0.35) | PDK1GAAMGAMTP53CYP3A4 | |
| SCHEMBL13634386 | 0.80 | GAA (0.35) | PDK1GAAMGAMTP53CYP3A4 | |
| SCHEMBL18291771 | 0.80 | GAA (0.35) | PDK1GAAMGAMTP53CYP3A4 | |
| SCHEMBL23158050 | 0.78 | GAA (0.34) | GAAMGAMTP53CYP3A4ALOX15 | |
| SCHEMBL25551655 | 0.78 | GAA (0.34) | GAAMGAMTP53CYP3A4ALOX15 | |
| SCHEMBL26003516 | 0.78 | PDK1 (0.34) | PDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242544-A1 | QUINAZOLINE COMPOUNDS, PREPARATION METHODS AND USES THEREOF | InventisBio Co., Ltd. (CN) | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242544-A1 | QUINAZOLINE COMPOUNDS, PREPARATION METHODS AND USES THEREOF | KRAS, NRAS, HRAS | PDK1 505/4885GAA 3489/4885MGAM 4544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.